Lead: Health officials in Maryland and federal disease trackers reported a small but notable rise in mumps cases in early 2026, prompting local alerts and renewed public-health attention. As of February 19, Maryland documented 26 cases this year (19 confirmed, seven probable), and the U.S. Centers for Disease Control and Prevention listed 34 cases across 11 jurisdictions in late February. The spike underscores that mumps—largely controlled by vaccination since the 1960s—can resurface in tightly connected communities. Public-health authorities are investigating transmission chains and advising testing, isolation and targeted vaccination measures.
Key takeaways
- Maryland has reported 26 mumps cases through February 19, 2026: 19 confirmed and seven probable, according to the Maryland Department of Health.
- The CDC reported 34 total U.S. cases across 11 jurisdictions as of late February 2026, highlighting multiple localized clusters rather than a single nationwide surge.
- Mumps incidence plummeted after the first vaccine approval in 1967—from 152,209 cases in 1968 to 231 cases in 2003—then began rising again after 2006.
- The MMR vaccine is not perfect: one dose is about 72% effective against mumps, two doses about 86%—breakthrough infections can occur but tend to be milder.
- Mumps incubation is typically 2–3 weeks; people are contagious several days before gland swelling and for about five days after symptoms start.
- Serious but uncommon complications include orchitis, oophoritis, meningitis, encephalitis and permanent hearing loss; unvaccinated people face the highest risk of severe outcomes.
- During outbreaks, public-health agencies may recommend a third MMR dose for those at increased risk (e.g., college students, health-care workers, close-contact groups).
Background
Mumps was once a near-universal childhood infection in the United States. The introduction of the mumps vaccine and later the combined measles-mumps-rubella (MMR) formulation in the late 1960s produced a dramatic decline in reported cases. The CDC records a fall from more than 150,000 annual cases in the late 1960s to a few hundred by the early 2000s. That decline reflected broad uptake of routine childhood immunization and changes in public-health reporting.
However, since about 2006, public-health authorities have documented more frequent mumps outbreaks, often centered in settings with prolonged close contact—colleges, military barracks, camps and some workplaces. Several factors are thought to contribute: imperfect vaccine effectiveness against mumps compared with measles, waning immunity over time, dense social networks that favor transmission, and occasional introduction of the virus into susceptible groups.
Stakeholders include state and local health departments that track cases and issue guidance; the CDC, which compiles national surveillance data and issues outbreak recommendations; clinicians who diagnose and manage cases; and institutions such as universities that implement targeted vaccination or isolation policies. The current Maryland cluster sits within this broader pattern of intermittent outbreaks rather than sustained widespread transmission.
Main event
Maryland health officials issued an alert after confirming 26 cases of mumps by February 19, 2026. The state’s report separates those into 19 laboratory-confirmed infections and seven probable cases identified through clinical and epidemiologic criteria. Local investigators are working to map contacts, identify transmission venues and advise exposed individuals on testing and quarantine.
At the national level, the CDC tallied 34 mumps cases across 11 jurisdictions as of late February 2026, indicating multiple geographically distinct clusters. The agency and state partners are monitoring whether cases remain limited to small groups or begin to seed broader community spread. Early responses typically include testing symptomatic individuals, recommending five-day isolation after symptom onset, and reviewing vaccination records within affected groups.
Clinicians note the characteristic sign—swelling of one or both parotid salivary glands—along with fever, headache, muscle aches and fatigue. Because people can be contagious before gland swelling starts, investigators prioritize rapid contact tracing in close-contact environments such as dormitories and athletic teams. Public-health messaging stresses that, while many infections in children are mild or asymptomatic, adolescents and adults may experience more pronounced symptoms and a higher risk of complications.
Analysis & implications
The resurgence of mumps in pockets illustrates a tension in vaccine-preventable disease control: high overall coverage reduces population risk, but imperfect vaccine durability and intense local exposure can permit outbreaks. Two-dose MMR programs dramatically reduce case counts and severity, yet immunity to mumps appears to wane more than for measles, contributing to vulnerability in young adults who were vaccinated in childhood.
Institutions with dense social mixing—colleges, some workplaces and congregate living settings—remain fertile ground for transmission once the virus is introduced. That means public-health responses must combine routine vaccination, swift testing and isolation, and, when appropriate, targeted booster doses. The CDC’s guidance for outbreak response emphasizes a pragmatic use of an additional MMR dose for those at elevated exposure risk rather than broad population-level revaccination.
Economically and operationally, even small outbreaks impose costs: clinic visits, diagnostic tests, lost class time or workdays, and targeted vaccination campaigns. For health systems, the priority is preventing severe complications and limiting disruption through rapid containment. International travelers and health-care personnel represent additional focal groups for ensuring up-to-date immunity.
Comparison & data
| Year (landmark) | Reported U.S. mumps cases |
|---|---|
| 1968 | 152,209 |
| 2003 | 231 |
| 2026 (as of late Feb; selected jurisdictions) | 34 (CDC total across 11 jurisdictions) |
The table contrasts the dramatic decline in annual U.S. case counts after vaccine rollout with the small, recent uptick reported in early 2026. Although the 2026 totals remain tiny compared with pre-vaccine years, the distribution of cases—clustered in close-contact groups—matters more for outbreak management than raw national totals. Public-health tools that worked in earlier eras remain effective but must be applied swiftly to limit secondary spread.
Reactions & quotes
“People can spread mumps before they notice swelling, which makes early detection and isolation crucial in close-contact settings.”
Dr. Leana Wen, CNN wellness expert and emergency physician
Dr. Wen’s observation underpins public-health advice prioritizing rapid testing and five-day isolation after symptom onset to reduce onward transmission.
“The recent increase in our reported cases prompted an alert to clinicians and the public as we work to interrupt transmission chains.”
Maryland Department of Health (official statement)
The state statement accompanied case counts and local mitigation steps, including contact tracing and guidance on testing and vaccination status checks for exposed groups.
Unconfirmed
- The precise transmission source for the Maryland cluster is under investigation and not yet publicly confirmed.
- The degree to which vaccine-derived immunity wanes for different birth cohorts is still being refined; estimates vary across studies.
- Claims that the current cases signal a nationwide resurgence are unsupported by the available surveillance numbers, which currently show localized clusters rather than broad spread.
Bottom line
Small clusters of mumps in early 2026 show that vaccine-preventable diseases can re-emerge in specific contexts even when overall coverage is strong. Vaccination remains the primary defense: two MMR doses greatly reduce the likelihood of infection and lower the risk of serious complications when breakthrough cases occur.
Public-health responses that combine rapid testing, temporary isolation for cases, contact tracing and targeted additional MMR doses for high-risk groups are the most effective way to control outbreaks. Individuals should verify vaccination records, stay home and seek testing if symptomatic, and consult health-care providers about booster doses if recommended by local authorities.
Sources
- CNN (news report) — media report summarizing state and CDC data and expert commentary.
- U.S. Centers for Disease Control and Prevention (CDC) — federal public-health surveillance and guidance (official).
- Maryland Department of Health — state public-health alerts and case counts (official).